The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal
subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of
tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this
patient population.
Funding Source - FDA Office of Orphan Products Development
Phase:
Phase 2
Details
Lead Sponsor:
E. Sander Connolly
Collaborators:
Food and Drug Administration (FDA) University of Florida University of Washington